NEW YORK (GenomeWeb) – Fitch Ratings has affirmed Thermo Fisher Scientific's ratings and its stable rating outlook.

The ratings apply to $12.5 billion of debt as of Dec. 31, 2015 and include BBB ratings for Thermo Fishers' long-term issuer default rating, senior notes, and a bank revolving credit facility; and F2 ratings for its short-term IDR and commercial paper. Fitch also affirmed a BBB rating for Thermo Fisher Subsidiary Life Technologies' long-term IDR and senior notes.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.